Genprex's Reqorsa Shows Promise in Lung Cancer Preclinical Trials
Event summary
- Genprex collaborators presented positive preclinical data on Reqorsa® gene therapy for lung cancer at the 2026 AACR Annual Meeting.
- TROP2 and PTEN identified as potential biomarkers for primary resistance to Reqorsa® in NSCLC.
- Reqorsa® demonstrated tumor shrinkage and boosted Natural Killer (NK) cell antitumor activity in preclinical studies.
- Combination of Reqorsa® and alectinib showed synergistic effects in ALK+ NSCLC models.
The big picture
Genprex's positive preclinical data for Reqorsa® in lung cancer highlights the growing potential of gene therapy in oncology. The identification of biomarkers for resistance and the demonstration of synergistic effects with existing treatments could position Reqorsa® as a significant player in the precision medicine landscape. The company's ability to translate these findings into clinical success will be critical for its strategic positioning in the competitive oncology market.
What we're watching
- Clinical Translation
- Whether the preclinical success of Reqorsa® can be replicated in human clinical trials.
- Combination Therapies
- The potential of Reqorsa® as an adjunct therapy to re-sensitize resistant tumors.
- Regulatory Pathway
- The pace at which Genprex can advance Reqorsa® through FDA approval processes.
Related topics